Skip to content

Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation

Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16010168
Enrollment
Unknown
Registered
2016-12-15
Start date
2016-12-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

propofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery
dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged=18 years, ASA physical status I-III, undergoing selective deep brain stimulation, agree to inform consent and follow-up

Exclusion criteria

Exclusion criteria: Patients with body mass index (BMI)> 30kg/m2 or 180mmHg and / or diastolic blood pressure> 110mmHg). Severe cardiovascular disease and patients known or suspected allergy to anesthetics (propofol, remifentanil, dexmedetomidine and so on).

Design outcomes

Primary

MeasureTime frame
the ability of patient to cooperate in macrostimulation testing;Modified OAA/S scale;Postoperative relief of disease in patients;

Secondary

MeasureTime frame
VAS pain scores;Total postoperative consumption of analgesic,in mg,of through 24 hours;the incidence of vomiting and nause in the first 24h after operation;

Countries

China

Contacts

Public ContactLi Yu

West China Hospital, Sichuan University

biaojieli@tom.com+86 18980601545

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026